PITTSBURGH and TORONTO, March 15,
2012 /PRNewswire/ -- Mylan Pharmaceuticals ULC, the Canadian
subsidiary of Mylan Inc. (NASDAQ: MYL), today received approval
from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg,
10mg, 20mg and 40mg. Mylan-Rosuvastatin is the generic version of
Astra Zeneca's Crestor® Tablets, which are used for the management
of primary hypercholesterolaemia, mixed dyslipidaemia, and familial
hypercholesterolaemia. According to IMS Health, Rosuvastatin
Calcium Tablets, 5mg, 10mg, 20mg and 40mg, had Canadian sales of
approximately $742 million for the 12
months ending Dec. 31, 2011.
"We are very pleased to introduce Mylan-Rosuvastatin to the
Canadian market," said Dick Guest,
president of Mylan Canada.
"According to the Canadian Heart and Stroke Foundation, 'about 40%
of Canadians have high blood cholesterol.'[1] Not only does this
introduction provide Canadians with access to our quality medicine,
it does so at a substantially lower cost. The introduction of
generic medicines like Mylan-Rosuvastatin helps to contribute to a
sustainable health care system."
Currently, Mylan Canada has 42
product applications pending Health Canada approval representing
$3.6 billion in annual sales,
according to IMS Health.
In Canada, generic drugs cost consumers an average of 60% less
than their brand name counterparts.
Mylan-Rosuvastatin is contraindicated in patients who are
hypersensitive to it and in patients with active liver
disease. Pregnant women or women wishing to become pregnant
should not take Rosuvastatin, as well as patients taking
cyclosporine.
About Mylan
Mylan Inc. ranks among the leading generic and specialty
pharmaceutical companies in the world and provides products to
customers in more than 150 countries and territories. The company
maintains one of the industry's broadest and highest quality
product portfolios supported by a robust product pipeline; operates
one of the world's largest active pharmaceutical ingredient
manufacturers; and runs a specialty business focused on
respiratory, allergy and psychiatric therapies. For more
information about Mylan in Canada,
please visit www.mylan.ca. For more information about generic
drugs, please visit www.ChoosingGenerics.ca.
[1]
http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm
SOURCE Mylan Pharmaceuticals ULC